EMA Recommendations on Compassionate Use of Remdesivir for COVID-19


Applied Clinical Trials

During a virtual meeting held on April 2nd, EMA’s human medicines committee gave recommendations on how the investigational antiviral medicine remdesivir should be used for treating coronavirus disease in compassionate use programs. 

To read the reccomendations, click here.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
© 2023 MJH Life Sciences

All rights reserved.